Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sisomicin: Bacteriological and clinical evaluation.

J Klastersky, C Hensgens, M Gérad

    Journal of Clinical Pharmacology
    |April 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Bacteremia due to Stomatococcus mucilaginosus in neutropenic patients in the setting of a cancer institute.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2003
    Same author

    Febrile neutropenia and Fusobacterium bacteremia: clinical experience with 13 cases.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2003
    Same author

    [Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party].

    Revue des maladies respiratoires·1998
    Same author

    Lung fibrosis induced by paclitaxel.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·1998
    Same author

    [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].

    Revue medicale de Bruxelles·1998
    Same author

    [Gemcitabine: a new chemotherapy agent for solid cancers].

    Revue medicale de Bruxelles·1998

    Sisomicin, a new aminoglycoside antibiotic, shows high efficacy in treating urinary tract and wound infections caused by gram-negative bacteria. This preliminary study found the drug to be well-tolerated with infrequent toxic reactions in patients.

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Clinical Microbiology

    Background:

    • Aminoglycoside antibiotics are crucial for treating Gram-negative bacterial infections.
    • Emerging antibiotic resistance necessitates the evaluation of new antimicrobial agents.
    • Sisomicin represents a novel aminoglycoside with potential therapeutic applications.

    Purpose of the Study:

    • To evaluate the efficacy and safety of sisomicin in patients with bacterial infections.
    • To determine the optimal dosage range for sisomicin therapy.
    • To assess the incidence of adverse events associated with sisomicin administration.

    Main Methods:

    • A preliminary clinical study involving 40 patients.
    • Administration of sisomicin at varying doses (1.5 to 3.75 mg/kg/day).

    Related Experiment Videos

  • Monitoring treatment outcomes for urinary tract and wound infections.

    • Main Results:

    • Sisomicin demonstrated high effectiveness in urinary tract infections (91.6% favorable results).
    • The antibiotic showed moderate efficacy in wound infections (66.6% favorable results).
    • Adverse reactions affecting hearing, renal function, and general tolerance were infrequent (<5%), with transient granular casts noted in 22% of patients.

    Conclusions:

    • Sisomicin is an effective therapeutic option for Gram-negative rod infections, particularly urinary tract infections.
    • The antibiotic exhibits a favorable safety profile with low incidence of significant toxicities.
    • Further investigation into sisomicin's clinical utility is warranted.